GSK-Hansoh Osteosarcoma drug succeeds in Phase III studies

July 28 (Reuters) - GSK plc GSK.L:

• GSK PLC - Hansoh positive 2nd Phase III results for riz-rez
• GSK - Artemis-011 Phase III study meets primary endpoint in relapsed osteosarcoma
• GSK - Ris-rez shows significant improvement in progression-free survival versus chemotherapy
• GSK - No new safety signals identified in Artemis-011 study
• GSK - Hansoh Pharma to use data for regulatory submission in China
• GSK: For ris-rez consistent benefit was also observed across secondary endpoints, including overall survival

Source text: ID:nRSb1879Oa

Further company coverage: GSK.L